New hope for young patients with tough hodgkin lymphoma: CAR T-Cells after transplant
NCT ID NCT06617286
First seen May 04, 2026 · Last updated May 21, 2026 · Updated 5 times
Summary
This study tests whether giving special immune cells (CAR T-cells) after a strong chemotherapy and stem cell transplant is safe and possible for children, teens, and young adults with poor-risk Hodgkin lymphoma. About 21 participants will receive the treatment to see how well it works and what side effects occur. The goal is to better control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical College
Valhalla, New York, 10595, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.